RecruitingNCT03194971

NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy

Sponsor

Medical College of Wisconsin

Enrollment

20 participants

Start Date

Jun 1, 2017

Study Type

OBSERVATIONAL

Conditions

Glioblastoma

Summary

This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Newly diagnosed glioblastoma, World Health Organization (WHO) grade IV, patients undergoing TTField therapy.
Recurrent glioblastoma WHO grade IV, patients undergoing TTField therapy.

Exclusion Criteria4

TTField compliance \< 75%.
Any contraindication to Optune TTField treatment.
Initial brain tumor diagnosis \< WHO grade IV.
Duration of TTField therapy \< 3 months.

Interventions

OTHERTumor samples from patients treated with TTFields at initial diagnosis.

Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.

DEVICETumor samples from patients treated with TTFields at tumor recurrence.

Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.